Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2012 5
2013 4
2014 2
2015 2
2016 5
2017 9
2018 51
2019 72
2020 105
2021 120
2022 126
2023 121
2024 48

Text availability

Article attribute

Article type

Publication date

Search Results

570 results

Results by year

Filters applied: . Clear all
Page 1
Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer.
Chi KN, Agarwal N, Bjartell A, Chung BH, Pereira de Santana Gomes AJ, Given R, Juárez Soto Á, Merseburger AS, Özgüroğlu M, Uemura H, Ye D, Deprince K, Naini V, Li J, Cheng S, Yu MK, Zhang K, Larsen JS, McCarthy S, Chowdhury S; TITAN Investigators. Chi KN, et al. N Engl J Med. 2019 Jul 4;381(1):13-24. doi: 10.1056/NEJMoa1903307. Epub 2019 May 31. N Engl J Med. 2019. PMID: 31150574 Free article. Clinical Trial.
BACKGROUND: Apalutamide is an inhibitor of the ligand-binding domain of the androgen receptor. ...The frequency of grade 3 or 4 adverse events was 42.2% in the apalutamide group and 40.8% in the placebo group; rash was more common in the apalutamide group. .. …
BACKGROUND: Apalutamide is an inhibitor of the ligand-binding domain of the androgen receptor. ...The frequency of grade 3 or 4 adver …
Apalutamide in Patients With Metastatic Castration-Sensitive Prostate Cancer: Final Survival Analysis of the Randomized, Double-Blind, Phase III TITAN Study.
Chi KN, Chowdhury S, Bjartell A, Chung BH, Pereira de Santana Gomes AJ, Given R, Juárez A, Merseburger AS, Özgüroğlu M, Uemura H, Ye D, Brookman-May S, Mundle SD, McCarthy SA, Larsen JS, Sun W, Bevans KB, Zhang K, Bandyopadhyay N, Agarwal N. Chi KN, et al. J Clin Oncol. 2021 Jul 10;39(20):2294-2303. doi: 10.1200/JCO.20.03488. Epub 2021 Apr 29. J Clin Oncol. 2021. PMID: 33914595 Clinical Trial.
Herein, we report final efficacy and safety results after unblinding and placebo-to-apalutamide crossover. METHODS: Patients with mCSPC (N = 1,052) were randomly assigned 1:1 to receive apalutamide (240 mg QD) or placebo plus ADT. ...RESULTS: With a median follow-up …
Herein, we report final efficacy and safety results after unblinding and placebo-to-apalutamide crossover. METHODS: Patients with mCS …
Apalutamide and Overall Survival in Prostate Cancer.
Smith MR, Saad F, Chowdhury S, Oudard S, Hadaschik BA, Graff JN, Olmos D, Mainwaring PN, Lee JY, Uemura H, De Porre P, Smith AA, Brookman-May SD, Li S, Zhang K, Rooney B, Lopez-Gitlitz A, Small EJ. Smith MR, et al. Eur Urol. 2021 Jan;79(1):150-158. doi: 10.1016/j.eururo.2020.08.011. Epub 2020 Sep 6. Eur Urol. 2021. PMID: 32907777 Free article. Clinical Trial.
Subsequent life-prolonging therapy was received by 371 (46%) patients in the apalutamide arm and by 338 (84%) patients in the placebo arm including 59 patients who received apalutamide after crossover. ...There was a 22% reduction in the hazard of death in the ap …
Subsequent life-prolonging therapy was received by 371 (46%) patients in the apalutamide arm and by 338 (84%) patients in the placebo …
Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer.
Smith MR, Saad F, Chowdhury S, Oudard S, Hadaschik BA, Graff JN, Olmos D, Mainwaring PN, Lee JY, Uemura H, Lopez-Gitlitz A, Trudel GC, Espina BM, Shu Y, Park YC, Rackoff WR, Yu MK, Small EJ; SPARTAN Investigators. Smith MR, et al. N Engl J Med. 2018 Apr 12;378(15):1408-1418. doi: 10.1056/NEJMoa1715546. Epub 2018 Feb 8. N Engl J Med. 2018. PMID: 29420164 Free article. Clinical Trial.
BACKGROUND: Apalutamide, a competitive inhibitor of the androgen receptor, is under development for the treatment of prostate cancer. ...The rate of adverse events leading to discontinuation of the trial regimen was 10.6% in the apalutamide group and 7.0% in the pla …
BACKGROUND: Apalutamide, a competitive inhibitor of the androgen receptor, is under development for the treatment of prostate cancer. …
Apalutamide.
[No authors listed] [No authors listed] 2023 Mar 15. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. 2023 Mar 15. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. PMID: 31643283 Free Books & Documents. Review.
Apalutamide is a third generation, oral nonsteroidal antiandrogen used to treat nonmetastatic castration-resistant prostate cancer. Apalutamide is associated with a low rate of serum enzyme elevation during therapy but has not been linked to cases of clinically appa …
Apalutamide is a third generation, oral nonsteroidal antiandrogen used to treat nonmetastatic castration-resistant prostate cancer. …
Deep, rapid, and durable prostate-specific antigen decline with apalutamide plus androgen deprivation therapy is associated with longer survival and improved clinical outcomes in TITAN patients with metastatic castration-sensitive prostate cancer.
Chowdhury S, Bjartell A, Agarwal N, Chung BH, Given RW, Pereira de Santana Gomes AJ, Merseburger AS, Özgüroğlu M, Juárez Soto Á, Uemura H, Ye D, Brookman-May SD, Londhe A, Bhaumik A, Mundle SD, Larsen JS, McCarthy SA, Chi KN. Chowdhury S, et al. Ann Oncol. 2023 May;34(5):477-485. doi: 10.1016/j.annonc.2023.02.009. Epub 2023 Feb 27. Ann Oncol. 2023. PMID: 36858151 Free article. Clinical Trial.
By 3 months of apalutamide treatment, best deep PSA decline of 90% or to 0.2 ng/ml occurred in 59% and 51% of apalutamide- and in 13% and 18% of placebo-treated patients, respectively. ...Similar results were observed at landmark 6 and 12 months of apalutamide …
By 3 months of apalutamide treatment, best deep PSA decline of 90% or to 0.2 ng/ml occurred in 59% and 51% of apalutamide- and …
Apalutamide for prostate cancer.
[No authors listed] [No authors listed] Aust Prescr. 2019 Feb;42(1):32-33. doi: 10.18773/austprescr.2018.072. Epub 2018 Dec 13. Aust Prescr. 2019. PMID: 30765908 Free PMC article. Review. No abstract available.
Apalutamide, Darolutamide and Enzalutamide for Nonmetastatic Castration-Resistant Prostate Cancer (nmCRPC): A Critical Review.
Cattrini C, Caffo O, De Giorgi U, Mennitto A, Gennari A, Olmos D, Castro E. Cattrini C, et al. Cancers (Basel). 2022 Mar 31;14(7):1792. doi: 10.3390/cancers14071792. Cancers (Basel). 2022. PMID: 35406564 Free PMC article. Review.
Nonmetastatic castration-resistant prostate cancer (nmCRPC) represents a condition in which patients with prostate cancer show biochemical progression during treatment with androgen-deprivation therapy (ADT) without signs of radiographic progression according to conventional imag …
Nonmetastatic castration-resistant prostate cancer (nmCRPC) represents a condition in which patients with prostate cancer show biochemical p …
Apalutamide and its use in the treatment of prostate cancer.
Borno HT, Small EJ. Borno HT, et al. Future Oncol. 2019 Feb;15(6):591-599. doi: 10.2217/fon-2018-0546. Epub 2018 Nov 14. Future Oncol. 2019. PMID: 30426794 Free PMC article. Review.
Progression to bone metastases is associated with significant morbidity and high cost. Apalutamide, an androgen receptor inhibitor, has substantial clinical response in nonmetastatic castration-resistant prostate cancer. Apalutamide + androgen deprivation therapy is …
Progression to bone metastases is associated with significant morbidity and high cost. Apalutamide, an androgen receptor inhibitor, h …
Apalutamide: First Global Approval.
Al-Salama ZT. Al-Salama ZT. Drugs. 2018 Apr;78(6):699-705. doi: 10.1007/s40265-018-0900-z. Drugs. 2018. PMID: 29626324 Review.
Apalutamide (Erleada(TM)) is a next-generation oral androgen receptor (AR) inhibitor that is being developed by Janssen for the treatment of prostate cancer (PC). ...This article summarizes the milestones in the development of apalutamide leading to this first appro …
Apalutamide (Erleada(TM)) is a next-generation oral androgen receptor (AR) inhibitor that is being developed by Janssen for the treat …
570 results